News | April 06, 2022
Revenue growth to moderate, non-Covid-19 revenue to drive profitability
Ind-Ra maintains a neutral outlook for healthcare in FY23
Ind-Ra maintains a neutral outlook for healthcare in FY23
The new facility is scheduled to start operation in the first half of 2024
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Casper Pharma is a Hyderabad based SEZ company engaged in the formulations business. Post-purchase of shares, the target entity would become a wholly-owned subsidiary of SPL
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Supply increase to help meet growing global demand
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
He has done his Masters in Pharmacy (M. Pharm) and Post Graduate Diploma in Personnel Management & Industrial Relations
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
Subscribe To Our Newsletter & Stay Updated
